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Abstract
Introduction GnRH (gonadotropin-releasing hormone) ana-
logues are long-term known to be safe and effective in the
clinical management of hormone-dependent advanced pros-
tate cancer. However, their unusual mechanism of action of
de-sensitizing pituitary receptors makes generic market entry
challenging. In addition, safety aspects like initial flare-up,
breakthrough escape, and miniflares render planning and or-
ganization of clinical registration trials a complex project.
Regulatory requirements: therapeutic equivalence Regulatory
requirements are high as these medicines are compared to
bilateral surgical castration with a 100 % success rate. GnRH
analogues will be used probably even wider in the near future
due to demographic development and extension of indications.
However, they are challenged by their antagonistic counter-
parts, which are avoiding flare-up phenomena. The following
article deals with regulatory requirements of GnRH analogues
in regard to their clinical characteristics.
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Prostate cancer is one of the most common malignancies
worldwide and is a leading cause of morbidity and mortality
in elderly men. In many countries of the industrialized world,
it represents the most frequently newly diagnosed cancer in
men [1]. According to data published by the American Cancer
Society, more than 200,000 Americans were diagnosed with
prostate cancer in 2013. Prostate cancer is the second leading
cause of cancer deaths in the USA. It is estimated that about
one in six men in the USA will be diagnosed with prostate
cancer during their lifetime and 1 in 36 will die from this
disease [2]. In Europe, there are more than 380,000 new cases
each year, representing more than 22 % of cancers diagnosed
in men. Prostate cancer is the most numerous cancer diag-
nosed in men and is the third most common cause of death
through malignancy in men in Europe [3]. The precise etiol-
ogy of prostate cancer is unknown, but in the overwhelming
majority, its growth is dependent on testosterone as the main
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driver. However, testosterone itself is not responsible for
oncogenic transformation but the main driver after the disease
has occurred. Consequently, androgen deprivation causes re-
mission or clinical improvement in a high proportion of local-
ly advanced or metastatic prostate cancer. Approximately
75 % of patients with metastatic prostate cancer present tumor
response to initial endocrine therapy. Antiandrogenic endo-
crine therapy is therefore the first and primary tool of clini-
cians in systemic treatment of patients with metastatic prostate
cancer. Thus, GnRH (gonadotropin-releasing hormone) ana-
logues play a pivotal role in clinical management of higher
stages (T3–T4) of prostate cancer.
Mechanism of action and indications of GnRH analogues
GnRH agonists are synthetic analogues of gonadotropin-
releasing hormone (synonymous: GnRH, gonadorelin, lutein-
izing hormone-releasing hormone (LHRH)). The different sub-
stances are chemically synthesized usually in the form of a
Merrifield synthesis [4] and are, therefore, not biological me-
dicinal products. Thus, from a regulatory perspective, the over-
arching guideline for biosimilars does not apply for generic
market entry [5]. An alignment of their amino acid sequence
compared to the endogenous hormone and general information
on licensed substances are provided in Fig. 1 and Table 1.
Endogenous GnRH is released in a pulsatile manner approxi-
mately every 1–2 h. When given as a bolus in a nonretarded
formulation, GnRH analogues like the hormone itself induce
gonadotropin (luteinizing hormone (LH) and follicle-
stimulating hormone (FSH)) secretion and, subsequently, stim-
ulation of gonadal function. In contrast, long-term treatment
with depot formulations causes downregulation and de-
sensitization of GnRH receptors in the pituitary gland. As a
consequence, the levels of testosterone in men and estradiol in
women, respectively, are diminished. In men, LH released from
the anterior pituitary gland stimulates the testes to produce
testosterone. In women, FSH and LH cause the production of
estrogen and progesterone to control the female cycle.
Physiological LH release results in a transient surge in
serum testosterone levels (flare-up). However, continuous,
unphysiological stimulation of LH secretion over extended
periods of time by either repeated administration of GnRH or
single administration of long-acting GnRH analogues results
in downregulation of pituitary GnRH receptors by which
gonadotropin secretion is dramatically reduced, resulting in
gonadal suppression, with decreased testosterone production
in men and estradiol production in women.
Accordingly, due to the inhibition of LH secretion by
chronic administration, GnRH analogues are effective in the
treatment of androgen-dependent prostate cancer in men [6]
and hormone-dependent breast cancer in pre- and perimeno-
pausal women [7]. In addition, GnRH analogues have a useful
role in the management of some benign estrogen-dependent
gynecological disorders like endometriosis and uterine fi-
broids [8]. However, pharmacokinetics (PK) are quite differ-
ent in women compared to men [9]. Thus, from a regulatory
perspective, clinical data recorded in male patients cannot
justify an approval of female indications, irrespective of
whether it is a benign or malign indication.
Pharmacokinetics of GnRH analogues
Given that most clinical evidencewas gathered with goserelin,
the following characteristics are described for the originator
Fig. 1 Alignment of the primary
protein structure of GnRH
analogues compared to the
endogenous hormone
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Zoladex®. However, in different countries, different prefer-
ences for certain GnRH analogues exist [10]. After adminis-
tration of the 3-month (3 M) goserelin implant at a dose of
10.8 mg, a maximum concentration (Cmax) of 8 to 10 ng/mL is
reached within 2 h (tmax) after administration with a second
peak plasma concentration 7 weeks after administration of the
implant.
Plasma protein binding of goserelin is low, ranging be-
tween 20 and 30 %. The apparent volumes of distribution
determined after subcutaneous administration of a rapid-
release aqueous solution were 44±13 L for males and 20±
4 L for females, respectively, suggesting a distribution into
total body water. However, this points to substantial differ-
ences in PK parameters between men and women.
Hydrolysis of the C-terminal amino acids is the major clear-
ance mechanism of goserelin and other GnRH analogues. The
metabolism of goserelin in humans is comparable to the profile
of metabolites from animal studies: All metabolites found in
humans have also been detected in preclinical animal studies.
Clearance of goserelin following subcutaneous administration
of the rapid-release solution formulation is very rapid. It is
excreted primarily in urine. More than 90 % of the dose is
recovered in urine and only 2% in feces over a 5-day collection
period. More than 75 % of the dose is excreted within 12 h.
An elimination half-life (t1/2) of 4.2 h is observed in healthy
volunteers. In patients with prostate cancer, a similar t1/2 value
of 4.6 h is observed. The goserelin pharmacokinetic/
pharmacodynamic (PK/PD) relationship (measured using the
originator Zoladex®) is nonlinear (on-off response) and time-
dependent due to the de-sensitization of the pituitary gland
which is maintained with very low levels of goserelin once
achieved. However, the exact concentration required to de-
sensitize these receptors is not known. Thus, formal demon-
stration of bioequivalence alone is not meaningful to file
marketing authorization applications (MAA) for generic
GnRH formulations.
Regulatory requirements: therapeutic equivalence
According to their extraordinary mechanism of action,
exceptional rules apply when generic formulations of
GnRH analogues enter the market. As these substances
mechanistically exert their effect by receptor de-
sensitization, formal demonstration of bioequivalence is
not meaningful in this context. GnRH itself physiologi-
cally is released in a pulsatile manner with an incretion
burst approximately every 2 h (60–120 min). In contrast,
GnRH analogues, also referred to as “super agonists,”
stimulate the receptor over extended periods of time. This
unphysiologically long stimulation causes an endocrine
counteraction: GnRH analogues in this regard are a ho-
mogenous class of medicines exerting their effects by de-
sensitization of receptors in the anterior pituitary gland
rather than by single substance effects. As a consequence,
in male patients, plasma testosterone is diminished to
castration levels. Thus, reaching and maintaining castra-
tion levels of testosterone is the accepted surrogate in
generic registration trials. Given this, it is intuitive that
MAA cannot be filed under Article 10(1) of Directive
2001/83/EC (generic application) which would be
entailed with formal demonstration of bioequivalence. In
this class of substances, Article 10(3) (hybrid application)
is applied. Thus, instead of bioequivalence, therapeutic
equivalence is required at least by European agencies.
This is somehow different in parts of the so-called
pharmerging markets (i.e., South and Southeast Asia and
Brazil, where formal demonstration of bioequivalence of
the active substance is required). With respect to
testosterone-lowering treatment options, orchiectomy (bi-
lateral surgical castration) is considered the state-of-the-
art treatment for androgen deprivation therapies (ADT).
Thus, pharmacological therapies are compared to success
rates of surgical castration [11]. It is thereby easy to
Table 1 General information on GnRH analogues
INN name
(originator’s name)




Amino acid sequence (and chemical molecule variations)
GnRH (LHRH Ferring®) H01 CA 01 Solution for injection 1983 Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly Hormone
Buserelin (Profact®) L02 AE 01 Implant (depot) 1988 Pyr-His-Trp-Ser-Tyr-Ser-Leu-Arg-Pro Analogues
Goserelin (Zoladex®) L02 AE 03 Implant (depot) 1990 Pyr-Glu-His-Trp-Ser-Tyr-D-Ser(But)-Leu-Arg-Pro-Azgly
Histrelin (Vantas®) L02 AE 05 Implant (depot) 2008 5-Oxo-Pro-His-Trp-Ser-Tyr-Ntbenzyl-D-His-Leu-
Arg-N-ethyl-L-prolinamid
Leuprorelin (Enantone®) L02 AE 02 Microcapsules (retard) 1987 5-Oxo-Pro-His-Trp-Ser-Tyr-D-Leu-Arg-N-ethyl-L-prolinamid
Nafarenlin (Synarela®) H01 CA 02a Nasal spray 1995 5-Oxo-Pro-His-Trp-Ser-Tyr-3-(2-naphthyl)-
D-Ala-Leu-Arg-Pro-Gly
Triptorelin (Decapeptyl®) L02 AE 04 Solution for injection
(retard)
2001 Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly
a Only benign female indications
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understand why pivotal requirements for demonstrating
therapeutic equivalence are so high: Usually, 90 % of
patients must be successful in reaching and maintaining
castration level (primary efficacy variable).
In this regard, it must be mentioned that “castration level”
does not mean “zero level” could be reached. Ninety to ninety-
five percent of endogenous testosterone is produced by the
testes; however, a remaining source of the hormone derives
from adrenal secretion (~5 %). Within the recent years, experts
discussed whether lowering of the internationally accepted
castration level would make sense. In detail, lowering from
0.5 to 0.2 ng/mL is under debate. From the medicinal perspec-
tive, this issue is discussed in view of safety and efficacy.
Various publications propagate lowering castration level
for safety reasons [12]. Apart from theoretical discussions,
prospectively collected clinical data suggest lowering this
threshold [13]. This ongoing discussion also is mentioned in
medicinal guidelines. The Guidelines on Prostate Cancer of
the European Association of Urology (EAU, 2014) in this
regard states (p. 96) [11]:
12.2.1 Castration level
Surgical castration is still considered the ‘gold standard’
for ADT, against which all other treatments are rated. It
leads to a considerable decline in testosterone levels and
induces a hypogonadal status, known as the ‘castration
level’. The standard castrate level is < 50 ng/dL. It was
defined more than 40 years ago, when testosterone level
testing was limited. Current testing methods using
chemiluminescence have found that the mean value of
testosterone after surgical castration is 15 ng/dL. This
has led to a revisiting of the current definition of castra-
tion, with a more appropriate level defined as below 20
ng/dL (1 nmol/L).
From the regulatory perspective, lowering testosterone
castration level would have tremendous impact on generic
marketing applications. Case numbers would have to rise
substantially to manage the new challenge. However, it
remains questionable whether the innovator products
themselves would be successful: In the late 1980s, when
those substances entered the market, 0.2 ng/mL was not in
the discussion, and analytical methods to quantify testos-
terone blood levels post hoc nowadays are highly
questionable.
Other challenges in the approval process
End-of-dose phenomenon (acute-on-chronic phenomenon)
End-of-dose phenomena in the context of GnRH analogues
describe premature exhaustion of a depot formulation. As a
consequence, testosterone levels rise at the end of the dosage
interval (Fig. 2). In regard to the end-of-dose phenomenon,
regulators usually will advise dense dose sampling especially
at the end of each dosing interval. To this end, a single-dose
study will not be sufficient in a registration trial, and at least
two administrations of the study drug will be required because
otherwise an acute-on-chronic phenomenon cannot be exclud-
ed. Thus, a possible schedule could look like the one indicated
in Fig. 3.
Fig. 2 Premature exhaustion of a
3-month (3 M) depot formulation
of a given GnRH analogue as ex-
ample of the end-of-dose phe-
nomenon, also called acute-on-
chronic phenomenon (simulated
curve)
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Breakthrough escapes and miniflares
Along with the Vantas® referral [14], at first sight, things
seemed to become easier for generic market applications.
The European Medicines Agency (EMA) denied that a com-
parator arm would be pivotal in a registration trial pointing at
the a.m. biochemical surrogate and an internationally accepted
(and harmonized) threshold for castration. However, an in-
depth analysis of the situation uncovers dangerous traps and
pitfalls for applicants and CROs. Waiving the comparator arm
is at the applicant’s risk. In this regard, a closer look at
breakthrough escapes and miniflares is necessary.
Both are abruptly occurring transient escapes from castration
under ADT. The discussion on these phenomena is two-edged as
on the one hand, they seem to be rare. On the other hand,
throughout the last decade, the particular hazardousness of rising
testosterone under therapy was uncovered. Back in 2004, Chen
et al. already mentioned that “… These data… imply that (even)
a modest increase in receptor concentration permits the receptor
to function despite the lower levels of androgens in castrated
patients…” [15]. Attard et al. in 2009 discussed that pharmaco-
logical castration might hypersensitize prostate cancer cells to
remaining steroid concentrations in patients’ blood [16]. This
finding especially emphasizes that breakthrough escapes and/or
miniflares might be of eminent hazardousness for patients. In this
context, it is under debate whether the castration threshold must
be lowered to switch off mitogenic signaling of the androgen
receptor (AR). Various molecular mechanisms of hypersensitiza-
tion are known today, such as overexpression of AR-mRNA or
mutations of the receptor. In 2012, Galsky et al. summarized
these findings: “Prostate cancer that progresses despite castrate
levels of serum Testosterone have been historically referred to as
‘hormone-refractory’ or ‘androgen-independent’ disease.
Among the most significant advances in prostate cancer over
the past decade has been the realization, that these tumors are not
in fact hormone refractory, but may instead be hormone
ultrasensitive” [17]. In this context, the US-American guidelines
of the National Comprehensive Cancer Network [18] point to the
following recommendations (p. 21): “Androgen receptor activa-
tion and autocrine/paracrine androgen synthesis are potential
mechanisms of recurrence of prostate cancer during ADT
(ADT, Androgen Deprivation Therapy). Thus, castrate levels of
testosterone should be maintained while additional therapies are
applied.” Taken together, it is currently agreed by the scientific
community that breakthrough escapes and miniflares are partic-
ularly dangerous and should be avoided in daily patient care.
However, they are clearly differentiated from insufficient
galenic quality of the respective drug product which might
end up in premature exhaustion of the administered depot
(irrespective of whether it is an implant or consists of micro-
capsules). However, from the regulatory point of view, both
are regarded as therapy failures with respect to the primary
endpoint and might endanger the outcome of the whole trial as
90 % success rate easily is fallen below. Thus, one possible
way to circumvent this pitfall would be to enroll at least a
small comparator arm with complete pharmacokinetic charac-
terization. Breakthrough escapes and miniflares as well as an
ongoing discussion on lowering the castration level to 0.2 ng/
mLwere not an issue at the time the originator product entered
the market. Thus, their performance in these contexts simply
is not completely known. Taken together, waiving the com-
parator arm according to the Vantas® referral undoubtedly is a
legal option but associated with the described risks.
Box: abarelix and degarelix antagonists without flares?
A comparatively new treatment concept are GnRH antagonists. For
instance, degarelix (Firmagon®) was licensed via the central European
approval procedure [19]. Abarelix (Plenaxis®) was approved by the
FDA in 2003. Compared to GnRH analogues, the castration level
usually is reached without initial testosterone flare-up within 1 week (+
antiandrogen flare protection) in the relief of lower urinary tract symp-
toms secondary to prostate cancer: results from a phase IIIb study
(NCT00831233) [20]. In clinical trials, one third of patients even reached
castration level after 3 days. Since pituitary receptors are neither down-
regulated nor de-sensitized, normalization of the testosterone level after
termination of therapy is reached more rapidly and side effects resolve
faster. However, safety profiles of antagonists are not completely known
at present. Antagonists show more injection side reactions, and ana-
phylactoid reactions with urticaria, hypotension, pruritus, and syncopes
were observed in 1.1 %. To this end, more clinical post-authorization
data are needed to come to a final conclusion.
An initial flare-up effect (Fig. 4) may cause serious symptoms such as
worsening of bone pain, ureteral obstruction, and spinal cord com-
pression [21, 22]. Thus, antagonists may be of clinical benefit espe-
cially in metastasized patients.
A regulatory outlook: current status and regulatory
prospects
Localized prostate cancer describes a stage where the tumor is
refined to the prostate and did not grow through the organ’s
Fig. 3 Possible schedule of blood sampling times to assess an end-of-dose phenomenon for a 3-month (3 M) depot formulation of a given GnRH
analogue
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capsule. It is staged cT1–T2 (and N0 M0) according to EAU
guidelines. Depending on TNM staging, watchful waiting
(WW), active surveillance (AS), or radical prostatectomy
(RP) might be an option and ADT is not indicated (or ap-
proved). However, throughout the recent years, earlier clinical
use of ADT has emerged in many countries all over the world.
Currently, it is questionable whether ADT in earlier stages of
prostate cancer is of clinical benefit. A growing body of
evidence seems to be in favor of this new concept, but mature
long-term data on clinical outcomes are not yet available as
summarized by Akaza [23]. According to their licensing sta-
tus, GnRH analogues become an option when the disease
already is in advanced stage (T3 or higher). Depot formula-
tions of GnRH analogues have been used to treat hormone-
dependent advanced prostate cancer for more than two de-
cades now. It is undoubted that these substances are effective
and a worthy tool for clinicians to (reversibly) castrate pa-
tients. Current data from the public domain also suggest a
combination of ADT and external-beam radiotherapy (RT).
However, some GnRH analogues are approved for combina-
tion treatment (triptorelin, leuprorelin) via national and de-
central European procedures, others not (yet). As combination
treatment already is recommended by European and US-
American medicinal guidelines of high evidence, currently,
there is a gap between clinical use and regulatory status of
these substances. Management of locally advanced prostate
cancer deals with both local control and the need to treat
micrometastases undetectable with imaging techniques.
Therefore, a multimodal strategy should apply as reflected in
medicinal guidelines in Europe and the USA. The major
treatment modalities currently proposed by the EAU in the
treatment of locally advanced prostate cancer are
& Radical prostatectomy (RP)
& Definitive radiotherapy (DR)
& Hormonal ablation therapy
or a combination of these. Various clinical studies have ad-
dressed whether a combined treatment of ADT and RT is of
clinical benefit.
Widmark et al. conducted a randomized, open phase III
study comparing endocrine therapy with and without local
radiotherapy, followed by castration on progression, in order
to assess the effect of radiotherapy [24]. This trial included
men from 47 centers throughout Scandinavia. Between 1996
and 2002, 875 patients with locally advanced prostate cancer
(78 % staged T3 N0 M0) were enrolled to receive either
endocrine treatment alone (3 months of total androgen block-
ade with leuprorelin followed by continuous endocrine treat-
ment using flutamide (n=439 patients)) or the same endocrine
treatment combined with radiotherapy (n=436 patients). The
authors concluded that in patients with locally advanced pros-
tate cancer, addition of RT to endocrine treatment halved the
10-year prostate cancer-specific mortality and substantially
decreased overall mortality with acceptable risk of side effects
compared with endocrine treatment alone.
Mottet et al. compared 3-year leuprorelin treatment (micro-
sphere formulation) plus radiotherapy with leuprorelin alone
in locally advanced prostate cancer patients [25]. This study
was a multicenter, randomized, open controlled phase III trial
in 264 histologically confirmed T3–T4 or pT3 N0M0 prostate
cancer patients randomized from March 2000 to December
2003. Patients received either 11.25 mg subcutaneous depot
injection of leuprorelin every 3 months for 3 years plus
external-beam radiotherapy (n=133) or leuprorelin alone
Fig. 4 Comparison of testosterone time course under therapywith GnRH
analogues (upper graph) and GnRH antagonists (lower graph), respec-
tively. In regard to initial flare-ups, concomitant therapy with androgen
receptor antagonists (flutamide, bicalutamide) is recommended within the
first 3 weeks of GnRH analogue therapy
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(n=133). Flutamide for flare-up prevention (750 mg/day) was
administered for 1 month. The authors concluded that com-
bined therapy of leuprorelin and radiotherapy strongly favored
improved PFS, locoregional control, and metastasis-free
survival.
EORTC 22863 is a randomized phase III trial assessing the
benefit of the addition of long-term androgen suppression
with a GnRH analogues (the authors used goserelin for this
study) to external irradiation in patients with prostate cancer
with high metastatic risk (10-year follow-up) [26]. The au-
thors concluded that in patients with prostate cancer with high
metastatic risk, immediate androgen suppression with an
GnRH analogue given during and for 3 years after external
irradiation improves 10-year disease-free and overall survival
without increasing late cardiovascular toxicity.
Apart from the a.m. studies, evidence in favor of combined
therapy also is provided by the Radiation Therapy Oncology
Group (RTOG) 85-31 [27], RTOG 86-10 [28], and RTOG 94-
08 [29]. Apart from clinical studies, epidemiological trials also
investigated this issue. Supporting studies on the effect of
ADT in combination with RT are the following:
& D’Amico et al. [30]
& Hanks et al. [31] and Horwitz et al. [32]
& Bolla et al. [33]
& Bekelman et al. [34]
& Crook et al. [35]
& Souhami et al. [36]
& Lawton et al. [37]
In addition, clinical studies are underway to investigate
whether long-term, short-term, or intermittent ADT is the best
option with regard to safety issues: GnRH analogues are
known to cause bone loss (eventually entailed with fractures).
RTOG 92-02 especially, published by Hanks et al. in 2003,
investigated this issue [31]. However, final judgment is not yet
possible, and this discussion is ongoing.
Conclusions
The current regulatory status of GnRH analogues is best
described as “in between state.” The traditional approach of
GnRH analogues as palliative medicines in locally advanced
or metastatic situations is currently challenged by clinical
practice to initiate ADT in earlier stages of the disease. At
the other end of the scale, ADT in advanced prostate cancer is
on its way to be widened (for not to say “flared”) also to
comprise combined ADT and RT as a multimodal approach.
Thus, GnRH analogues throughout the upcoming years will
remain important in clinical management of prostate cancer.
However, regulatory requirements are tremendous. For
granting marketing authorizations, it is pivotal to demonstrate
therapeutic equivalence for generic formulations on the basis
of testosterone suppression (currently 0.5 ng/mL) to castrate
levels in 90 % of cases or more. Galenic formulations must be
able to avoid end-of-dose premature exhaustion, and receptor
de-sensitization must be complete to avoid breakthrough es-
capes and/or miniflares. Whether GnRH antagonists will be a
clinical alternative or even substitute GnRH analogues re-
mains to be elucidated on the basis of clinical long-term
follow-up data. Taken together, clinical evaluation and filing
MAA will remain a huge challenge for the pharmaceutical
industry in this highly complex and regulated field.
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